Frost M, et al. - Researchers conducted phase 3, open-label, observational, multi-centre 48-week trial including 228 adults with opioid use disorder in order to assess the safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots in long-term. This trial was conducted at 26 out-patient sites (United States, United Kingdom, Hungary, Denmark, Sweden, Germany, Australia) between 14 December 2015 and 12 April 2017. One hundred sixty-seven of 227 (73.6%) participants completed the study treatment period. Observations revealed that patients had good tolerability to subcutaneous buprenorphine delivered weekly or monthly (CAM2038), with a systemic safety profile consistent with the known profile of sublingual buprenorphine. They noted high retention rates and low levels of illicit opioid use in correlation to CAM2038 weekly and monthly throughout this study.